A Study of Simbrinza™ Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02348476

Enrollment

150

Registered

2015-01-28

Start date

2014-11-30

Completion date

2015-04-30

Last updated

2015-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular Hypertension, Open-Angle Glaucoma

Brief summary

This study is a retrospective chart review to assess the tolerability and efficacy of treatment with Simbrinza™ used for patients with Open-Angle Glaucoma or Ocular Hypertension.

Interventions

OTHERNo Intervention

No study drug is administered in this study.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Participants treated with Simbrinza™ for Intra-Ocular Pressure (IOP) lowering in at least one eye * Participants who had at least one-follow-up visit with tolerablity and efficacy data after Simbrinza™ treatment initiation.

Exclusion criteria

* Active ocular disease other than glaucoma or ocular hypertension * History of any intraocular surgery or glaucoma laser surgery within 3 months.

Design outcomes

Primary

Measure	Time frame
The time to first glaucoma therapy escalation occurrence or discontinuation of Simbrinza®	2 Years

Secondary

Measure	Time frame
The time(s) to additional glaucoma therapy escalation occurrence(s)	2 Years
Specific AEs and SAEs occurring with a frequency of ≥5%	2 Years
The time to first glaucoma therapy escalation occurrence	2 Years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026